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Objective. Antimicrobial resistance has decreased eradication rates for Helicobacter pylori infection worldwide. To observe the
eﬀect of eradicating Helicobacter pylori (H. pylori) and the treatment of duodenal ulcer by 2 kinds of modiﬁed sequential therapy
through comparing with that of 10-day standard triple therapy. Methods. A total of 210 patients who were conﬁrmed in duodenal
u l c e ra c t i v eo rh e a lp e r i o db yg a s t r o s c o p ya n dH. pylori positive conﬁrmed by rapid urease test, serum anti-H. pylori antibody
(ELASE), or histological examination enrolled in the study. All the patients were randomly divided into three groups: group
A (70 cases) and group B (70 cases) were provided 10-day modiﬁed sequential therapy; group C (70 cases) was provided 10-
day standard triple therapy. Patients of group A received 20mg of Esomeprazole, 500mg of Clarithromycin for the ﬁrst 5 days,
followed by 20mg of Esomeprazole, 500mg of Clarithromycin, and 1000mg of Amoxicillin for the remaining 5 days. Group
B received 20mg of Esomeprazole, 1000mg of Amoxicillin for the ﬁrst 5 days, followed by 20mg of Esomeprazole, 500mg
of Clarithromycin, and 1000mg of Amoxicillin for the remaining 5 days. Group C received 20mg of Esomeprazole, 500mg of
Clarithromycin, and 1000mg of Amoxicillin for standard 10-day therapy. All drugs were given twice daily. H. pylori eradication
rate was checked four to eight weeks after taking the medicine by using a 13C urea breath test. In the ﬁrst, second, third, seventh,
twenty-ﬁrst, thirty-ﬁfth days respectively, the symptoms of patients such as epigastric gnawing, burning pain, and acidity were
evaluated simultaneously. Results. Overall, 210 patients accomplished all therapy schemes, 9 case patients were excluded. The
examination result indicated that the H. pylori eradication rate of each group was as follows: group A 92.5% (62/67), group
B 86.8% (59/68), and group C 78.8% (52/66). The H. pylori eradication rate of group A was slightly higher than group B
(P<0.05) and both of them were obviously higher than group C (P<0.05). Modiﬁed sequential therapy was signiﬁcantly
more eﬀective in patients with clarithromycin-resistant strains (80%/67% versus 31%; P = 0.02). Symptoms improvement: all
the three groups could improve the symptoms such as epigastric gnawing, burning pain, and acidity since the ﬁrst day. There
was no signiﬁcant diﬀerence in total score descending of symptoms between each group (P>0.05). Conclusions.A l lt h et h r e e
therapy schemes could alleviate symptoms of duodenal ulcer patients in China eﬃciently. But as far as eradicating H. pylori
is concerned, the modiﬁed sequential therapy was better than standard triple therapy, especially the therapy scheme used in
group A.2 Gastroenterology Research and Practice
1.Introduction
Helicobacter pylori (H. pylori, Hp) plays a crucial role in the
pathogenesis of chronic gastritis, peptic ulcer disease (gastric
ulcer, duodenal ulcer), gastric-mucosa-associated lymphoid
tissue (MALT) lymphoma, and gastric adenocarcinoma. H.
pylori is a major cause of illness and death worldwide
[1]. The treatment of duodenal ulcer mainly depended on
H. pylori eradication and proton pump inhibitor (PPI).
Obvious eﬀect was also achieved. Helicobacter pylori treat-
ment still remains a challenge for physicians, and no current
ﬁrst-line therapies are able to cure the infection in all treated
patients [2]. The standard H. pylori eradication therapy in
China consists of a triple-drug regimen containing a proton
pump inhibitor(bismuth) and clarithromycin, with either
amoxicillin or an imidazole [3]. Indeed, during the last
few years, diﬀerent studies have found that the success rate
following such regimens is disappointingly low, with values
less than 45–60% in some countries [4]. This phenomenon
most likely depends on an increased bacterial resistance
to antibiotics, particularly against clarithromycin the key
antibiotic in H. pylori treatment [5]. However, it has also
been concerned about the eradication rates with those
regimens decreased due to emergence of metronidazole
resistance in H. pylori over the past few years. GUO et al.
[6] have reported that prevalence of metronidazole-resistant
H. pylori strains has increased to more than 70% in China.
Two large meta-analyses [7, 8] showed that these therapies
failed to eradicate H. pylori in up to 20% of patients. Even
lower cure rates have been observed in primary medical
care settings, with bacterial eradication being achieved in
only 61% to 76% of patients. So we need new treatment
regimens.
De Francesco et al. [9] discovered a new program to
eradicate H. pylori sequential therapy, which can obtain
a higher eradication rate, but related reports in China
are still not abundant. Novel 10-day sequential therapy
consisting of 5-day dual therapy (proton pump inhibitor
plus amoxicillin) followed by 5-day triple therapy (proton
pump inhibitor, Clarithromycin, and tinidazole) had good
eradicationsuccessinunblindedtrialsinelderlypatients[10,
11]. This study compared two kinds of modiﬁed sequential
therapy and a kind of conventional triple therapy to explore
the diﬀerence in eradication of H. pylori and treatment of
duodenal ulcer and such improvement of symptoms. Our
study achieved some meaningful results as follows.
2.MaterialsandMethods
2.1. General Data of Patients. This was a comparative, paral-
lel, open-label, multicenter, randomized study. It was carried
out between January 2007 and July 2009.
Criteria of inclusion: (1) age 15–70 years old, no restrict
gender, (2) duodenal ulcer inactive and heal period con-
ﬁrmed by gastroscopy in seven days, (3) intensive positive
in rapid urease test (RUT) and H. pylori (Hp)-positive
conﬁrmed by serum anti-Hp antibody, stained slice, or
histological examination, and (4) approve to participate the
eﬃciency observation.
Criteria of exclusion: (1) patients who had gastric ulcer
or severe gastroesophageal reﬂux disease must take proton
pump inhibitor (PPI), patients who had gastrectomy history,
patients who had hemolytic anemia or family history, (2)
patientswhowereinlactationorpregnancy,(3)patientswho
had combined severe disease of other system that may aﬀect
the medical evaluation of this study, (4) patients who took
the drugs of this study in one month, (5) patients who was
allergic to the drugs in this study, and (6) patients who had
dysfunction of heart, liver, and kidney.
Criteria of suspension: (1) patients who had poor com-
pliance and could not take medicine at arrangement, (2)
patients who combined application of other treatment such
as acid inhibitor and antiacid medicine, and (3) patients
who were considered should not take the medicine by doctor
according to their beneﬁt because adverse accident hap-
pened. These results of case patients did not participate in
eﬀect statistic but in safety evaluation, and (4) patients who
couldnotreexamintimeorlost.Allparticipantsgavewritten
informed consent.
2.2. Therapy Regimens. In each center, all patients were ran-
domly assigned using a computer-generated list to one of
the following treatments. Group A and group B were pro-
vided 10-day modiﬁed sequential therapy. Group C was
provided 10-day standard triple therapy. Patients of group A
received 20mg of Esomeprazole, 500mg of Clarithromycin
for the ﬁrst 5 days, followed by 20mg of Esomeprazole,
500mg of Clarithromycin, and 1000mg of Amoxicillin
for the remaining 5 days. Group B received 20mg of
Esomeprazole, 1000mg of Amoxicillin for the ﬁrst 5 days,
followed by 20mg of Esomeprazole, 500mg of Clar-
ithromycin, and 1000mg of Amoxicillin for the remaining
5 days. Group C received 20mg of Esomeprazole, 500mg
of Clarithromycin, and 1000mg of Amoxicillin for stan-
dard 10-day therapy. All drugs were given twice daily.
Esomeprazole (40mg/tab, 010672, pharmaceutical Co. Ltd),
clarithromycin (250mg/tab, 030501, Hangzhou Chinese-
American East China Pharmaceutical Co. Ltd), and Amox-
icillin (500mg/tab, 011003, Pharmaceutical factory).
For each therapy regimen, the proton pump inhibitor
was prescribed before breakfast and supper, whereas all
antibiotics were given after these meals. Patients were asked
to return at the end of the antibiotic treatment to assess
the compliance with therapy and to estimate the incidence
of side eﬀects. Compliance was deﬁned as consumption of
greaterthan90%oftheprescribeddrugsandwasdetermined
bypillcountsatthefollowupvisit.Sideeﬀectswereevaluated
using a structured questionnaire by personal interview.
2.3. Items Observed and Examined. Illness history clinical
symptom was recorded and gastroscopy was executed to
clarify the disease diagnosis and status of H. pylori infection.
During the gastroscopy examination, four biopsy specimens
were taken from gastric antrum: one for RUT, one forGastroenterology Research and Practice 3
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Figure 1: Study regimen.
stained slice, and two additional biopsy samples for bacterial
culture and susceptibility testing. For this purpose, biopsy
specimens were sent to a single microbiological laboratory in
Shanghai within 24 hours and were stored at −70◦C. Isolated
strains were considered to be resistant to clarithromycin
and amoxicillin if minimal inhibitory concentrations were
≥1ug/mL and ≥0.8ug/mL, respectively. Serum anti-Hp
antibody was also probed (ELASE). The patients who were
intensive positive in RUT (show red in ﬁve minutes) could
be considered qualiﬁed. Those who were suspected to be
H. pylori positive would take additional examinations by
silver dying and improved Giemsa dying. Besides RUT
positive, all participants must be positive in anti-Hp anti-
body, H. pylori dying, and histological examination. In
d1, 2, 3, 7, 21, and 35, the symptoms of patients such
as epigastralgia, burning pain, and acidity were evaluated;
the adverse reaction and the compliance of the patients
were also assessed. Bacterial eradication was checked 28 to
56 days after the treatment ﬁnished by using a 13C-urea
breath test. Figure 1 shows the ﬂow of patients through the
study. The other outcome was to determine the eﬃcacy of
sequential treatment against clarithromycin-resistant strains
of H. pylori.
2.4. Symptoms Score and Eﬀect Evaluation. The symptoms
during the ﬁrst day and at the end of 2, 3, 7, 21, and 35
days were monitored by scoring symptoms. Symptoms score,
included the symptoms of epigastralgia, burning pain, and
acidity. Score criteria: score 0 for no symptoms; score 1 for
slight, symptoms could be remarked; score 2 for medium,
had chief complaint of symptoms but did not aﬀect daily
life; score 3 for severe, had symptoms and aﬀected daily life.
Each patient was taught how to evaluate and make a record
on a diary card. Criteria of total eﬀect evaluation [12, 13]:
obvious eﬀect for the rate of score descending higher than
75%; eﬀect for the rate higher than 50% but lower than 75%;
progressfortheratehigherthan25%butlowerthan50%;no
eﬀect for the rate lower than 25%. Symptoms improvement4 Gastroenterology Research and Practice
evaluation: disappearance rate of chief symptoms was the
rate of chief symptoms disappearing entirely; alleviation rate
was the rate of symptoms improvement including obvious
eﬀect, eﬀect, and progress. Safety evaluation: safety compare
of diﬀerent schemes treatment.
Endoscopic images before and after therapy were con-
sidered another indicator of eﬀective treatment. For the
purposes of this study, the duodenal ulcer was conﬁrmed in
active or heal period by gastroscopy in seven days. Endo-
scopists in each center received training before the trial
started and two copies of pictures from every patient were
sent to the leading center for repeat reviewing. Safety moni-
toring was also conducted according to the recorded adverse
events.
2.5. Cost Calculations. T h ec o s to fe a c ht r e a t m e n tw a se s t i -
mated by using retail US costs obtained from our study.
The retail cost of the medications in China was as follows:
500mg of amoxicillin, $0.16; 250mg of clarithromycin,
$0.75; 20mg of Esomeprazole, $2.13. The calculated costs
for 10-day modiﬁed sequential therapy and standard ther-
apy were $75.6 (Group A), $63.8 (Group B), and $78.8
(Group C), respectively. The cost of sequential therapy was
cheaperthanstandardtripletherapy.Therefore,themodiﬁed
sequential therapy is an economical alternative to standard
triple therapy.
2.6. Statistical Analysis. The sample size was a priori cal-
culated based on available data in the literature [14]. By
hypothesizing a 95% eradication rate for the sequential
regimen and 80% for 10-day triple therapy, it was calculated
that at least 68 patients per treatment arm were needed
to ﬁnd a statistically signiﬁcant diﬀerence with a level of
P<0.05 and a power of 0.85 [15]. H. pylori eradication
rate was the main analytic target. Total eradication rate
and its 95% conﬁdence interval of each scheme were
calculated and analyzed by ITT (intention to treat analysis)
and PP (per-protocol analysis), respectively. The eradication
rate diﬀerence of each scheme and degree of symptoms
improvement were made signiﬁcant check by Fisher exact
probability and Chi-square test, the signiﬁcant level was
deﬁnite P<0.05. The diﬀerent signiﬁcance of adverse
reactionincidencerateofeachschemewasanalyzedbyFisher
exact probability test.
3. Results
3.1. General Data. There were total 210 patients enrolled in
the study, 201 patients accomplished actually (95.7%), and 9
patients were lost (4.3%). Details of groups division were as
follows: group A, 67 patients, 40 patients male, 27 patients
female, 15–69a, mean 38 ± 10a, 3 patients lost; group B, 68
patients, 43 patients male, 25 patients female, 17–70a, mean
36 ± 11a, 2 patients lost; group C, 66 patients, 40 patients
male, 26 patients female, 18–69a, mean 37 ± 10a, 4 patients
lost. The gender, age structure, and lost patients of the three
groups had no signiﬁcant distinction (P>0.05) (Table 1).
Table 1: Characteristics of patients entering the intention-to-treat
analysis.
Group A
(n = 67)
Group B
(n = 68)
Group C
(n = 66)
P value
Age (mean ±SD,
years) 38 ±10 36 ±11 37 ±10 0.6
Sex
Male 40 43 40 0.1
Female 27 25 26 0.1
SD: standard deviation.
Table 2: Helicobacter pylori eradication rates with sequential and
standard therapy both at intention-to-treat (ITT) and per protocol
(PP) analyses.
Analysis Group A Group B Group C
ITT (%)∗ 62/70 (88.6%) 59/70 (84.3%) 52/70 (74.3%)
95% CI 80.3 to 92.9 79.2 to 93.2 63.5 to 78.8
PP (%)† 62/67 (92.5%) 59/68 (86.8%) 52/66 (78.8%)
95% CI 79.2 to 95.8 78.0 to 94.6 65.9 to 84.6
All patients who took at least 1 dose of medication are included. ∗Group
A versus Group B therapy: P = 0.4; Group A versus Group C therapy:
P = 0.03; Group B versus Group C therapy: P = 0.04; †Group A versus
Group B therapy: P = 0.02; Group A versus Group C therapy: P = 0.01;
Group B versus Group C therapy: P = 0.02.
3.2. Eﬀect and Symptoms Improvement Analysis. All the three
groups could improve the symptoms such as epigastralgia,
burning pain and acidity since the ﬁrst day. There was no
signiﬁcant distinction in total score descending of symptoms
between each group (P>0.05). There was no signiﬁcant dis-
tinction in total eﬃciency rate of duodenal ulcer treatment,
disappearance rate, and alleviation rate of chief symptoms of
the three groups (P>0.05) (Figure 2).
3.3. H. Pylori Eradication Rate. The result of H. pylori
eradication rate examination indicated that by per-protocol
analysis (PP) the H. pylori eradication rate of group A was
92.5% (62/67), the rate of group B was 86.8% (59/68), the
rate of group C was 78.8% (52/66), and by intention-to-treat
analysis(ITT)therateofgroupAwas88.6%(62/70),therate
of group B was 84.3% (59/70), and the rate of group C was
74.3% (52/70). The H. pylori eradication rate of group A was
slightly higher than group B (P<0.05), and both of them
were obviously higher than group C (P<0.05) (Table 2).
3.4. Role of Primary Resistance on Eradication of Helicobac-
terPylori Infection. Bacterial culture was successful in 178 of
210 (85%) patients. Isolated clarithromycin resistance was
present in 24 of 210 (13.5%) strains. No bacterial resistance
to amoxicillin was observed. In sequential therapy, the
prevalence of primary bacterial resistance to clarithromycin
was 5 of 70 (7.1%) and 6 of 70 (8.6%) patients, respectively.
Instandardtherapy,theprevalenceofstrainsresistanttoclar-
ithromycin was 13 of 70 (18.6%) patients. The eradication
rate was 80% and 67%, respectively in patients with isolated
clarithromycin resistance who received sequential therapyGastroenterology Research and Practice 5
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Figure 2: The trend of duodenal-ulcer-associated symptoms in the four groups. Time courses of the mean value of symptom scores are
shown in the graphs. The x-axis represents days from baseline and the y-axis represents the change rate of symptom score in DU patients.
(The lines represent the trend rather than a continuous variable).
compared with 31% of patients who received standard
therapy. However, the diﬀerence was not statistically sig-
niﬁcant in patients with clarithromycin susceptible strains,
receiving the modiﬁed sequential regimen comparing with
those receiving standard treatment (89%/86% versus 84%,
P = 0.71).
3.5. Adverse Reaction. Both treatments were well tolerated
and no patient was withdrawn from the study. The most
frequent adverse reaction related to the treatment was gas-
troenteric reaction. Of all the patients, group A had 8 cases,
group B had 6 cases, and group C had 7 cases. But all the
adverse reactions of each group were relatively slight. The
compliance of patients was well (Table 3).
4. Discussion
Helicobacter pylori (H. pylori) is a common type of bacteria
that usually infects people during childhood. In almost 50%
of cases, the infection does not cause symptoms. However,
some people with H. pylori infection eventually develop
inﬂammation of the stomach (gastritis) or ulcers in the
stomach or upper small intestine [5, 16–18]. Gastritis and
ulcers cause abdominal pain and, sometimes, bleeding.
H. pylori causes signiﬁcant morbidity and mortality with
a relevant economic impact, thus requiring an appropriate
therapeutic approach. A triple therapy, comprising proton
pump inhibitor, clarithromycin, and amoxycillin or metron-
idazole, is among the most used ﬁrst-line treatments in
primary medical care in several countries including Canada,6 Gastroenterology Research and Practice
Table 3: Patients with self-reported adverse events during therapy.
Adverse Event (n) Group A
(n = 67)
Group B
(n = 68)
Group C
(n = 66)
Epigastric pain 4 3 5
S k i n R a s h 102
Headache 2 2 0
Glossitis 0 0 0
A n e r g y 000
F e v e r 010
drowsiness 1 0 0
Total, n (%) 8 (11.9) 6 (8.8) 7 (10.6)
the United States, and Europe [14, 15, 19–21]. Doctors
often treat stomach pain and ulcers caused by H. pylori
with a combination of several antibiotics that are given for
several days. Some data conﬁrm the ﬁnding of disappointing
eradication rates after standard triple therapy, as widely
reported in several recent studies [22–30]. Indeed, one of
every six patients with peptic ulcer disease remained infected
after standard therapy [29]. In recent years, there has been
increasing resistance to standard antibiotic treatments for H.
pyloriinfection[31–33].Thismeansthatitishardertogetrid
of H. pylori in some patients and that we need new treatment
regimens.
Low eradication rates have been reported with standard
therapy in the United States, Europe, Australia, and Asia
[4, 34, 35]. Our study conﬁrms these reports on the low
success rates of infection eradication with standard therapy.
This may be mainly due to clarithromycin resistance. After
a decade of clarithromycin-based treatments and continued
widespread use of long-acting macrolides in generalpractice,
10% to 15% of H. pylori strains are resistant de novo to
clarithromycin [36]. As a result, the failure rate is around
20% for triple combination therapy (PPI plus amoxicillin
plus clarithromycin), which was so eﬀective when it was
ﬁrst evaluated 10 years ago [37, 38]. Because persistent H.
pylori in patients with ulcer can cause continuing ulcer
complications,afailurerateof20%alsomeansthateveryone
needs follow-up proof of cure. In addition, the 20% of
patients with persistent H. pylori warrant repeated attempts
at eradication with ever-decreasing success. A systematic
review of therapy for H. pylori reported a 53% decrease
in eradication rates if clarithromycin resistance was present
and if a clarithromycin-containing regimen was used [39].
Clarithromycin resistance is a major problem in many
western countries. Prevalence is 12.9% in the United States
and may be as high as 24% in some European countries [40–
42].
In contrast, we found a high H. pylori eradication rate
using the sequential regimen. It was signiﬁcantly greater
than that of standard triple therapy. Moreover, the sequential
treatment showed high eﬃcacy (>90%) in patients with
peptic ulcer disease and nonulcer dyspepsia [43]. Sequential
therapy for Helicobacter pylori refers to the idea of adding
more antibiotics to the treatment regimen but giving them
in sequence rather than giving all 4 drugs together. In a large,
prospective, controlled study in 2007, Vaira and colleagues
[43] showed a 90% cure rate for this “new” treatment
versus 80% for the “old.” In this issue, Jafri and colleagues
[44] perform a meta-analysis of clinical trials of sequential
therapy. Staggering the treatment with multiple antibiotics
does not increase side eﬀects but still eradicates almost
all H. pylori isolates, the exceptions being doubly resistant
isolates. Thus, sequential therapy combines the initial and
the repeated therapy in 1 treatment sequence, for the same
cost and with the same side eﬀect proﬁle as those of the
present standard therapy.
The precise mechanism for the success of the sequential
therapy is not known; however, bacteria can develop eﬄux
channels for clarithromycin, which rapidly transfer the drug
out of the bacteria cell, preventing the antibiotic from
binding to the ribosome [45]. Because amoxicillin acts on
the bacterial cell wall and weakens it, the initial phase of
treatment may prevent the development of eﬄux channels
by weakening the cell wall of the bacterium [45]. This
may improve the eﬃcacy of clarithromycin in the second
phase of treatment. The higher eﬃcacy of the sequential
regimen may be related to the larger number of antibiotics
(3 drugs) to which the organism is exposed with this
regimen or to the use of tinidazole, which is not contained
in the standard triple-drug regimen. Sequential therapies
are relatively new, and few data on these regimens are in
the literature [43]. A MEDLINE search to May 2011 by
using the keywords “sequential therapy” and “Helicobacter
pylori” yielded 168 citations. Recently Uygun A and col-
leagues [46] perform a study to compare the eradication
success of a 14-day sequential regimen with proton-pump-
inhibitor-based triple treatment. They found that a 14-day
sequential treatment regimen achieved a signiﬁcantly higher
eradication rate of H. pylori compared with standard PPI-
based triple regimen in this selected population. Hsu and
colleagues [47] showed that there was a multicenter pilot
study in which H. pylori-infected patients received a 14-day
sequential-concomitant hybrid therapy (esomeprazole and
amoxicillin for 7 days followed by esomeprazole, amoxicillin
clarithromycin, and metronidazole for 7 days). The eradi-
cation rate was 99.1% (95% conﬁdence interval (CI), 97.3–
100.0%) by per-protocol analysis and 97.4% by intention-
to-treat analysis (95% CI, 94.5–100.0%). Cost is a major
consideration in many countries. The cost of the sequential
regimen is similar to that of the standard regimen in China,
which makes it an attractive and reasonable alternative to
triple therapy [48–50].
Sequential therapy is currently suggested as ﬁrst-line
therapy in curing Helicobacter pylori infection, but results
coming from its use in clinical practice are scarce [51]. We
evaluated the eﬃcacy of this therapy regimen in our current
clinical practice. The results of this study show that modiﬁed
sequential therapy is superior to triple therapy for the erad-
ication of H. pylori infection. Our study also demonstrates
that additional antibiotic can improve eﬀect. Triple therapy,
which is the current standard treatment, has low eradication
rates. In conclusion, our large, prospective, controlled studyGastroenterology Research and Practice 7
shows the superiority of sequential treatment for eradicating
H. pylori infection in duodenal ulcer patients compared
with conventional triple therapy. All treatments were well
tolerated and had similar rates of side eﬀects and low rates
of patients who withdrew from the study. Our study suggests
that modiﬁed sequential therapy may have a role as a ﬁrst-
line treatment for H. pylori infection in duodenal ulcer
patients in China. Modiﬁed sequential regimen seems to be
a valid therapeutic strategy for the management of H. pylori
infection in clinical practice.
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